Skip to main content
    E

    Eledon Pharmaceuticals Inc (ELDN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.27
    +0.02 (+0.89%)

    Market Cap: $190.15M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(21/37)
    Avg Surprise
    -4.59%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.19
    Range$-0.21 - $-0.15
    4 analysts
    EPS Revisions
    1
    0
    7d
    1
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.18-2.7%
    60d ago$-0.18-2.7%
    30d ago$-0.190.0%
    7d ago$-0.190.0%
    Current$-0.19
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.36
    Range$-0.47 - $-0.20
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.36---
    Sep 26EST
    		-$-0.19---
    Jun 26
    Reported Aug 13
    		$-0.19$-0.19+0.00%Beat-46.2%
    Mar 26
    Reported May 13
    		$-0.33$-0.26-26.92%Miss-312.5%
    Dec 25
    Reported Mar 19
    		$-0.10$-0.20+50.00%Beat+89.4%
    Sep 25
    Reported Nov 14
    		$-0.21$-0.25+16.00%Beat+34.4%
    Jun 25
    Reported Aug 14
    		$-0.13$-0.23+43.48%Beat+87.7%
    Mar 25
    Reported May 14
    		$-0.08N/A+73.33%Beat+76.5%
    Dec 24
    Reported Mar 20
    		$-0.95$-0.33-189.44%Miss-226.1%
    Sep 24
    Reported Nov 12
    		$-0.32$-0.31-3.23%Miss+8.6%
    Jun 24
    Reported Aug 19
    		$-1.06$-0.32-231.25%Miss-165.0%
    Mar 24
    Reported May 9
    		$-0.34$-0.33-3.03%Miss+54.7%
    Dec 23
    Reported Mar 28
    		$-0.29$-0.39+25.64%Beat+58.0%
    Sep 23
    Reported Nov 9
    		$-0.35$-0.41+14.63%Beat+52.1%
    Jun 23
    Reported Aug 10
    		$-0.40$-0.45+11.11%Beat+38.5%
    Mar 23
    Reported May 11
    		$-0.75$-0.74-1.35%Miss-8.7%
    Dec 22
    Reported Mar 30
    		$-0.69$-0.70+1.43%Beat-15.0%
    Sep 22
    Reported Nov 14
    		$-0.73$-0.69-5.80%Miss-10.6%
    Jun 22
    Reported Aug 11
    		$-0.65$-0.72+9.72%Beat-30.0%
    Mar 22
    Reported May 12
    		$-0.69$-0.68-1.47%Miss-21.1%
    Dec 21
    Reported Mar 24
    		$-0.60$-0.79+24.05%Beat+13.0%
    Sep 21
    Reported Nov 11
    		$-0.66$-0.65-1.54%Miss+88.0%
    Jun 21
    Reported Aug 12
    		$-0.50N/A+86.70%Beat+81.5%
    Mar 21
    Reported May 13
    		$-0.57$-0.32-78.13%Miss+83.7%
    Dec 20
    Reported Mar 30
    		$-0.69N/A+60.80%Beat+78.7%
    Sep 20
    Reported Nov 16
    		$-5.51$-1.75-214.86%Miss-39.1%
    Jun 20
    Reported Aug 14
    		$-2.70$-2.97+9.09%Beat+57.1%
    Mar 20
    Reported May 15
    		$-3.49$-2.88-21.18%Miss+62.7%
    Dec 19
    Reported Mar 17
    		$-3.24$-4.68+30.77%Beat+63.3%
    Sep 19
    Reported Nov 13
    		$-3.96$-7.29+45.68%Beat+40.5%
    Jun 19
    Reported Aug 13
    		$-6.30$-7.65+17.65%Beat-2.9%
    Mar 19
    Reported May 14
    		$-9.36$-8.73-7.22%Miss-44.4%
    Dec 18
    Reported Mar 28
    		$-8.82$-7.20-22.50%Miss-14.0%
    Sep 18
    Reported Nov 13
    		$-6.66$-7.20+7.50%Beat+72.0%
    Jun 18
    Reported Aug 7
    		$-6.12$-5.58-9.68%Miss+77.8%
    Mar 18
    Reported Apr 2
    		$-6.48$-5.22-24.14%Miss+76.5%
    Sep 17
    Reported Nov 8
    		$-7.74N/AN/ABeat-
    Jun 17
    Reported Aug 9
    		$-23.76N/A+51.11%Beat-
    Mar 17
    Reported May 3
    		$-27.54$-48.60+43.33%Beat-
    Dec 16
    Reported Mar 3
    		$-27.54$-55.08+50.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-2.73EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-110.70%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio7.90xQuick Ratio7.90x
    Trading Statistics
    Beta0.85Avg Volume841.26K
    52-Week High$4.6052-Week Low$1.35

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.41
    SMA 20$2.52
    SMA 50$2.95
    SMA 200$3.07
    EMA 10$2.40
    EMA 20$2.52
    EMA 50$2.84
    EMA 200$3.08

    MACD

    Line: -0.17Signal: -0.17Hist: 0.00

    ADX

    ADX: 17.9+DI: 14.9-DI: 25.1

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down100.0
    PSAR$2.56

    Bollinger Bands

    Upper Band$2.84
    Lower Band$2.20
    %B Position2529%(Upper)
    Band Width0.11

    RSI (14-Day)

    Oversold
    28.2

    Momentum Oscillators

    Stoch %K8.1
    Stoch %D9.3
    Williams %R-86.7
    ROC (10d)-6.8%
    Momentum-0.17
    CCI (20d)-143.7
    MFI (14d)30.9

    Volatility Measures

    ATR (14d)$0.15(6.4%)
    StdDev (20d)0.16
    Hist Vol49.8%(High)

    Volume Flow

    VWAP$2.28
    OBV-312.3K
    AD Line-19.3M
    CMF (20d)-0.243

    Volume Metrics

    Avg Vol (20d)860.5K
    Vol Ratio0.7x
    VWMA (20d)$2.55

    Pivot Points

    R3$2.47
    R2$2.42
    R1$2.33
    Pivot Point$2.28
    S1$2.19
    S2$2.14
    S3$2.05

    Advanced Oscillators

    TSI-39.46
    Ultimate Osc31.1
    KST-182.97

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$384,000$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0$88,000$0$0$0$94,000$0
    Gross Profit$0$0N/A$0$0$0$-88,000$0$0$0$-94,000$0
    Operating Expenses$22.87M$21.18M$21.48M$19.07M$24.73M$17.96M$24.70M$20.51M$14.50M$10.87M$10.34M$11.20M
    R&D$18.23M$17.20M$17.49M$14.97M$20.28M$13.53M$17.93M$16.52M$10.11M$7.41M$7.07M$7.93M
    SG&A$4.64M$3.98M$3.99M$4.10M$4.46M$4.43M$6.77M$3.99M$4.40M$3.46M$3.27M$3.27M
    Operating Income$-22,869,000$-21,181,000$-21,484,000$-19,070,000$-24,733,000$-17,964,000$-24,696,000$-20,510,000$-14,502,000$-10,869,000$-10,338,000$-11,198,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$8.76M$17.84M$0$0$0$0$19.49M$0$30.41M$12.76M$18.99M$0
    Income Before Tax$-31,630,000$-39,025,000$-10,412,000$-17,459,000$-11,216,000$-6,495,000$-44,186,000$76.97M$-44,907,000$-23,631,000$-29,324,000$-9,906,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-31,630,000$-39,025,000$-10,447,000$-17,459,000$-11,216,000$-6,495,000$-44,617,000$76.97M$-44,907,000$-23,631,000$-30,099,000$-9,906,000
    EBITDA$-31,630,000$-39,025,000$-10,412,000$-17,459,000$-11,216,000$-6,495,000$-44,186,000$76.97M$-44,907,000$-23,631,000$-29,230,000$-9,812,000
    EBIT$-31,630,000$-39,025,000$-10,412,000$-17,459,000$-11,216,000$-6,495,000$-44,186,000$76.97M$-44,907,000$-23,631,000$-29,324,000$-9,906,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ELDN

    News

    Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

    Eledon Pharmaceuticals announced an upcoming oral presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting. The presentation will feature patient-reported outcomes from the Phase 2 BESTOW trial...

    GlobeNewswire•10/6/26•Somewhat-Bullish

    Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

    Eledon Pharmaceuticals announced that it will deliver an oral presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting. The presentation will detail patient-reported outcomes from the Phase 2...

    Yahoo! Finance Canada•10/5/26•Somewhat-Bullish

    A kidney transplant study will spotlight what patients report on Oct. 23

    Eledon Pharmaceuticals (ELDN) announced that it will present patient-reported outcomes from its Phase 2 BESTOW trial at the American Society of Nephrology Kidney Week 2026. The presentation, scheduled for October 23...

    Stock Titan•10/5/26•Neutral

    Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

    Eledon Pharmaceuticals announced an upcoming oral presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting. The presentation will feature patient-reported outcomes from the Phase 2 BESTOW trial...

    GlobeNewswire•10/5/26•Somewhat-Bullish

    Eledon Gains 13% on Updated Phase 2 Trial Data

    Eledon Pharmaceuticals Inc. saw its shares rise 13% after presenting updated long-term data from its Phase 2 trial of tegoprubart...

    Orange County Business Journal•9/22/26•Bullish

    ELDN Valuation and Fair Value

    P/E
    -2.7x
    Forward P/E
    5.4x
    P/B
    7.8x
    See GNG's fair value

    ELDN Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -110.7%

    ELDN Competitors

    CompanyTicker
    Akebia TherAKBA
    Entrada Therapeutics IncTRDA
    Niagen Bioscience, Inc.NAGE
    Rxsight IncRXST
    Cybin IncCYBN
    Upstream Bio, Inc.UPB
    Exagen IncXGN
    Sharps Technology IncSTSS

    Sector: Healthcare

    ELDN Analyst Ratings

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    0
    Buy
    6
    Hold
    0
    Sell
    0
    Strong Sell
    0

    ELDN Bull Case vs Bear Case

    Bull case

    • 100.0% of ELDN's analyst ratings are Buy or Strong Buy.

    ELDN Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -4.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.19
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 2 down

    Frequently Asked Questions About ELDN

    Does ELDN pay dividends?

    Eledon Pharmaceuticals Inc (ELDN) does not currently pay a regular dividend.

    What is ELDN's market cap?

    Eledon Pharmaceuticals Inc (ELDN) has a market capitalization of $190.15M with a current stock price of $2.27.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In